当前位置:药药网 / 数据中心 / 儿科研究特征电子表格
Morphine sulfate
儿科标签批准日期
2021/6/2 0:00:00
特定指示/秒
Postoperative pain in pediatric patients 2 years through 17 years
标签更改摘要
- Safety and effectiveness of Morphine Sulfate Oral Solution (2 mg/mL and 4 mg/mL) have been established for the management of pediatric patients 2 to 17 years with acute pain severe enough to require an opioid analgesic when alternative treatments are inadequate.
- Use of Morphine Sulfate Oral Solution in this age group is supported by clinical evidence in adults and supportive data from an open-label, safety and pharmacokinetic study in pediatric patients 2 through 17 years with post-operative acute pain.
- Pharmacokinetic modeling and simulation indicate that an initial dose of 0.3 mg/kg to pediatric patients 2 years of age and older is expected to produce a maximum systemic exposure (Cmax) similar to that achieved after single dose administration of 10 mg Morphine Sulfate Oral Solution to adults.
- The safety profile in pediatric patients consisted primarily of opioid-related adverse reactions and is similar to that observed in adults.
- Safety and effectiveness of Morphine Sulfate Oral Solution (2 mg/mL and 4 mg/mL) have not been established for the management of pediatric patients 2 to 17 years of age with chronic pain severe enough to require an opioid analgesic when alternative treatments are inadequate.
- Safety and effectiveness of Morphine Sulfate Oral Solution (2 mg/mL and 4 mg/mL) have not been established in pediatric patients less than 2 years of age.
- Safety and effectiveness of Morphine Sulfate Oral Solution 20 mg/mL have not been established in pediatric patients.
- Information on dosing, adverse reactions, PK parameters, and clinical trials.
- Postmarketing study.